SLC7A11 and Parkinson disease: For instance, in the context of Parkinson’s disease, a neurodegenerative disorder characterized by the loss of dopaminergic neurons, with aging as a major risk factor, research indicates that treatment with Fer-1, a ferroptosis inhibitor, reduces p53 levels while increasing the expression of ferroptosis regulators such as SLC7A11 and GPX4, thereby mitigating cellular senescence (Li et al., 2021).